Liquidia/$LQDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Ticker
$LQDA
Sector
Primary listing
Employees
170
Headquarters
Website
Liquidia Metrics
BasicAdvanced
$2B
-
-$1.82
0.23
-
Price and volume
Market cap
$2B
Beta
0.23
52-week high
$29.94
52-week low
$9.71
Average daily volume
2.7M
Financial strength
Current ratio
2.494
Quick ratio
2.339
Long term debt to equity
1,026.012
Total debt to equity
1,319.264
Interest coverage (TTM)
-8.47%
Profitability
EBITDA (TTM)
-136.866
Gross margin (TTM)
69.29%
Net profit margin (TTM)
-784.54%
Operating margin (TTM)
-715.38%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-39.74%
Return on equity (TTM)
-389.13%
Valuation
Price to revenue (TTM)
100.145
Price to book
131.09
Price to tangible book (TTM)
241.82
Price to free cash flow (TTM)
-15.608
Free cash flow yield (TTM)
-6.41%
Free cash flow per share (TTM)
-1.486
Growth
Revenue change (TTM)
30.20%
Earnings per share change (TTM)
25.74%
3-year revenue growth (CAGR)
11.86%
3-year earnings per share growth (CAGR)
30.83%
What the Analysts think about Liquidia
Analyst ratings (Buy, Hold, Sell) for Liquidia stock.
Bulls say / Bears say
Liquidia generated $6.517 million in product sales in Q2 2025—the first full quarter of YUTREPIA commercial availability following FDA approval on May 23, 2025—demonstrating strong early market traction (SEC Form 10-Q)
As of June 30, 2025, Liquidia held $173.4 million in cash and cash equivalents and received a $50 million tranche from its Healthcare Royalty agreement upon first YUTREPIA sale, providing a robust runway into 2026 (SEC Form 10-Q; Liquidia HCRx Release)
Interim ASCENT trial data showed a median six-minute walk distance improvement of 31.5 meters at Week 16 with only 18.5% discontinuations and no drug-related adverse event discontinuations in PH-ILD patients, underscoring YUTREPIA’s favorable tolerability and efficacy profile (GlobeNewswire)
Liquidia’s net loss widened to $41.6 million in Q2 2025, up from $28.7 million in Q2 2024, reflecting ongoing high operating costs and delayed profitability (SEC Form 10-Q)
Selling, general and administrative expenses nearly doubled to $38.8 million in Q2 2025 from $19.9 million in Q2 2024, driven by increased headcount and legal fees associated with YUTREPIA commercialization and litigation (SEC Form 10-Q)
Service revenue declined to $2.3 million in Q2 2025 from $3.7 million in Q2 2024, primarily due to unfavorable gross-to-net returns and managed care adjustments under the Sandoz promotion agreement (SEC Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Liquidia Financial Performance
Revenues and expenses
Liquidia Earnings Performance
Company profitability
Liquidia News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Liquidia stock?
Liquidia (LQDA) has a market cap of $2B as of October 11, 2025.
What is the P/E ratio for Liquidia stock?
The price to earnings (P/E) ratio for Liquidia (LQDA) stock is 0 as of October 11, 2025.
Does Liquidia stock pay dividends?
No, Liquidia (LQDA) stock does not pay dividends to its shareholders as of October 11, 2025.
When is the next Liquidia dividend payment date?
Liquidia (LQDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Liquidia?
Liquidia (LQDA) has a beta rating of 0.23. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.